CMS has proposed new rules to speed up prior authorization for prescription drugs and make denials more transparent. The changes are not final yet, so patients should not expect immediate nationwide changes.
FDA says semaglutide supply is stabilizing, which changes when compounded GLP-1 products may be allowed. The agency is also warning about dosing mistakes, quality problems, and misleading marketing tied to compounded versions of semaglutide and tirzepatide.
CMS has proposed new rules that would extend prior-authorization interoperability requirements to prescription drugs. The plan would not end prior authorization, but it could make requests more electronic, more standardized, and faster to answer for some health plans.
The FDA updated its medical device shortage list on March 13, 2026, adding angiographic control syringes with rotating adapters and stereotactic breast biopsy needles. Shortages are not the same as recalls, but they can still affect scheduling, substitutions, and procedure planning.
CDC says U.S. measles cases continued to rise in April 2026, with most cases linked to outbreaks. For families, schools, and caregivers, the practical response is still the same: know the symptoms, check vaccination status, and act quickly if exposure is possible.
The FDA has accepted a filing to expand Gazyva for systemic lupus erythematosus, but the IV drug is not approved for broader lupus in the U.S. yet.
Walking getting slower or more uncomfortable? Peripheral artery disease can limit mobility even without classic calf pain, especially with vascular risks.
A randomized trial found methotrexate did not meaningfully improve inflammatory knee osteoarthritis, underscoring that proven knee OA care still matters most.
CDC’s latest measles update has many parents asking about babies under 12 months. Here’s when an early MMR dose may be advised and what to do after exposure.
Federal vaccine recommendation wording can shape no-cost coverage. Here’s how private plans, Medicaid, Medicare, and VFC may differ in 2026.
Measles cases are climbing. Here’s when babies 6 to 11 months may get an early MMR shot, why it does not replace routine doses, and what parents should do.
A new JAMA Internal Medicine estimate puts CT scan safety back in focus. Here’s what the model found, what it did not prove, and what to ask before imaging.
The FDA says phone settings or software problems can disrupt diabetes device alerts, raising the risk of missed low blood sugar warnings and delayed treatment.
A randomized trial in community health centers found that team-based support plus home blood pressure checks improved systolic pressure more than enhanced usual care.
CMS says it began enforcing updated hospital price transparency rules on April 1, 2026, but patients should still treat posted prices as a starting point.
Updated CDC pages show fall deaths are still rising in older adults. Here’s how fall prevention, bone health, screening, and Medicare coverage connect.
A new U.S. cholesterol guideline adds more emphasis to one-time lipoprotein(a) testing. Here’s who may want to ask and what the result can mean.
Original Medicare can pay for some hearing tests in 2026, but hearing aids are still usually excluded. Here is what changed, what did not, and what to compare.
A bigger physician pipeline is good news, but U.S. patients may still face waits and access problems as primary care, nursing, and public health shortages persist.
As of April 1, 2026, CMS is enforcing updated hospital price transparency rules. The files may be easier to compare, but they still are not your final bill.
Medicaid work requirements are edging closer, and the biggest risk may be paperwork. Here is what enrollees should do now to protect coverage before 2027.
CMS is proposing faster, more electronic drug prior authorization rules, but patients should know the policy is not final and current public data still leave big gaps.
End of content
End of content
